Published in Lab Law Weekly, August 3rd, 2007
This trend article is an immediate alert from NewsRx to identify the most recent news developments at Allos Therapeutics, Inc.
Report 1: Allos Therapeutics, Inc. (NASDAQ:ALTH) announced the initiation of patient enrollment in a Phase I/IIa open-label, multi-center study of sequential PDX (pralatrexate) and gemcitabine with vitamin B12 and folic acid supplementation in patients with relapsed or refractory non-Hodgkin's lymphoma (NHL) or Hodgkin's disease.
"We are excited to advance the development of this promising treatment regimen," said Pablo J. Cagnoni, M.D., Chief...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Lab Law Weekly